Screener
Castle Biosciences CSTL Business Segments — Other segment items
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Significant segment expenses: | ||
| Personnel costs | 58,367 | 52,200 |
| Organizational and marketing costs | 15,594 | 14,229 |
| Inventory usage | 6,437 | 4,731 |
| Clinical studies and publication costs | 2,542 | 2,085 |
| Professional services | 3,007 | 3,576 |
| Other segment items | 12,254 | 37,015 |
| Segment loss | $(14,522) | $(25,848) |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's business segments — other segment items?
- Castle Biosciences (CSTL) reported business segments — other segment items of $12.25M in Q1 2026.
- How has Castle Biosciences's business segments — other segment items changed year-over-year?
- Castle Biosciences's business segments — other segment items decreased by 66.9% year-over-year, from $37.02M to $12.25M.
- What is the long-term trend for Castle Biosciences's business segments — other segment items?
- Over 3 years (2022 to 2025), Castle Biosciences's business segments — other segment items has grown at a 95.2% compound annual growth rate (CAGR), from $8.8M to $65.5M.
- What does business segments — other segment items mean?
- Encompasses miscellaneous operating expenses or income items specific to the segment that do not fall into primary cost categories. Tracking this helps identify non-recurring or secondary operational impacts on segment performance.
Ask your AI about Castle Biosciences's business segments — other segment items.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude